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INTRODUCTION
Helicobacter pylori (H. pylori) is a spiral-shaped, Gram-nega-
tive bacillus first isolated in 1983 (1). H. pylori is the major
pathogen of chronic gastritis and peptic ulcer disease and is
strongly associated with gastric adenocarcinoma and lym-
phoma (2, 3). Triple therapy with two antibiotics and a pro-
ton pump inhibitor (PPI) has been recommended as the treat-
ment of choice for H. pylori infection (4, 5), producing an era-
dication rate of 70-80% in adults, but there have been few
large-scale trials of the efficacy of PPI-based triple eradication
therapy in children. In addition, H. pylori has shown antimi-
crobial resistance, which may be the cause of treatment fail-
ure in many patients (6-8). The aim of this study was to com-
pare the efficacy in pediatric patients of two triple eradica-
tion therapies commonly used in Korea.
MATERIALS AND METHODS
Patients
This is a retrospective study of 233 pediatric patients with
H. pylori infection at two tertiary general hospitals (Asan Med-
ical Center and Samsung Medical Center) between January
1999 and July 2004. Patients were excluded if they had un-
dergone previous treatment for H. pylori or if they had taken
any antibiotics or PPI in the 4 weeks prior to the study. Eso-
phagogastroduodenoscopy was performed in each patient prior
to treatment since all patients had suffered from dyspepsia or
upper abdominal pain suggestive of an organic disease. H.
pylori infection was diagnosed when both histology and a rapid
urease test showed positive result. 
Methods
While 141 of 233 children were initially treated with an
OAC regimen, and 92 of 233 children were initially treated
with a BAM regimen. Details of regimens were described in
Table 1. 
Definition of eradication
Efficacy was evaluated 12 weeks after the end of treatment
using a 13C-urea breath test (UBT), performed according to
a previously validated technique. Briefly, after a fasting base-
line sample breath collection, 13C-labelled urea was admin-
istered orally in water, and a second breath sample was col-
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Helicobacter pylori Infection
Triple therapy with bismuth subsalicylate, amoxicillin, metronidazole (BAM) or with
omeprazole, amoxicillin, clarithromycin (OAC) has been commonly used for the era-
dication of Helicobacter pylori infection. We compared the efficacy of these triple
therapies in children with H. pylori infection. We retrospectively analyzed results in
233 children with H. pylori infection and treated with OAC (n=141) or BAM (n=92).
Overall eradication rates of triple therapy with OAC and BAM were 74% and 85%,
respectively, which showed no statistical difference. Our study showed that the triple
therapy with BAM was more effective for the first-line eradication of H. pylori infec-
tion in Korean children, but has no statistical difference with OAC regimen.
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lected 20 min later. Breath samples were analyzed by isotope
ratio mass spectrometry (UBiT-IR300; Photal Otsuka Elec-
tronics, Japan) and 2.5  (subtraction of baseline from sam-
ple) was used as the cut-off value. 
Statistical analysis
Statistical comparison of the two regimens was performed
using with Fisher’s exact test. Data analysis was performed
using the Statistical Package for Social Science (version 10.0;
SPSS INC. Chicago, Illinois, U.S.A.). The level of significance
was set at 0.05.
RESULTS
The 233 children consisted of 115 males and 118 females
and mean age was 10 yr (ranged from 2 to 15 yr). There were
no demographic differences between the children treated with
the OAC and BAM regimens (Table 1).
Of the 141 children treated with the OAC regimen, 105
were UBT negative after treatment. Of the 36 children who
failed the OAC regimen, 26 were secondarily treated with
the BAM regimen, of whom 21 became UBT negative. 
Of the 92 children treated with the BAM regimen, 78 were
UBT negative after treatment. Of the 14 children who failed
the BAM regimen, 7 were secondarily treated with the OAC
regimen, of whom 6 became UBT negative (Fig. 1).
As the first-line therapies, the eradication rates of the OAC
and BAM regimens were 74% and 85%, respectively, and
the overall eradication rate of both first-line triple regimens
was 79% (Table 2). Although the BAM regimen was more
effective than the OAC regimen in eradicating H. pylori infec-
tion, the difference did not reach statistical significance (p=
0.07). As the second-line therapies, the eradication rates of
the OAC and BAM regimens were 86% and 81%, respec-
tively, and the overall eradication rate of both second-line
triple regimens was 82% (Table 3). Again, the difference
between the two regimens was not statistically significant
(p=0.53). After the second-line treatment, as both first and
second-line the overall eradication rate of the OAC and BAM
regimens was 90% (210/233).
DISCUSSION
The previous studies of H. pylori eradication according to
antibiotic regimens were rare in Korean children. Bae et al.
(9) reported 90% with BAM regimen in 1998, Choi et al.
(10) reported 82% with OAC regimen in 2002. Both results
were better than our results, which may reflect the increas-
ing rate of antibiotic resistance with time, although we did
not directly test the H. pylori sensitivity to antibiotics in this
population. Bae et al. (9) also reported that triple therapy with
BAM regimen was more effective and safe than dual thera-
py with bismuth subcitrate and amoxicillin, eradication rate
was 90% in group treated with triple regimen, 61% in group
treated with dual regimen. However there have been no re-
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Fig. 1. Treatment strategies and outcomes of the study population.
OAC, omeprazole+amoxicillin+clarithromycin; BAM, bismuth sub-
salicylate+amoxicillin+metronidazole; UBT, urea breath test.
*p value >0.05
OAC, omeprazole (1 mg/kg/ day)+amoxicillin (50 mg/kg/day)+clarith-
romycin (15 mg/kg/day); BAM, bismuth subsalicylate (8 mg/kg/day)+
amoxicillin (50 mg/kg/day)+metronidazole (20 mg/kg/day).
BAM (n=92) OAC (n=141)
Sex* (male/female) 40/52 73/67
Mean age±SD* (yr) 10.4±3.4 9.8±3.1
Table 1. Demographic characteristics of the study population
(n=233)
OAC, omeprazole+amoxicillin+clarithromycin; BAM, bismuth subsalicy-
late+amoxicillin+metronidazole; UBT, urea breath test.
UBT negative UBT positive
OAC 105 (74%) 36 (26%)
BAM 78 (85%) 14 (15 %)
Overall 183 (79%) 50 (21%)
Table 2. Eradication rate of Helicobacter pylori treated with first-
line triple regimens
OAC, omeprazole+amoxicillin+clarithromycin; BAM, bismuth subsalicy-
late+amoxicillin+metronidazole; UBT, urea breath test.
UBT negative UBT positive
OAC 6 (86%) 1 (14%)
BAM 21 (81%) 5 (19 %)
Overall 27 (82%) 6 (18%)
Table 3. Eradication rate of Helicobacter pylori treated with sec-
ond-line triple regimensTreatment of Helicobacter pylori in children 1039
ports on the comparison of eradication rate of between BAM
and OAC regimen in Korean children.
For effective treatment regimens, the treatment should ach-
ieve an eradication rate of over 80% on a rigorous intention
to treat basis and over 90% on a per protocol basis (11-13).
This result may imply per protocol analysis because we en-
rolled retrospectively the only children who completed the
prescribed regimen and followed up; therefore there needs a
better regimen to eradicate H. pylori in children more effec-
tively.
Result of susceptibility testing yields best treatment out-
come, however susceptibility testing is generally unavailable.
Therefore, study of antibiotic susceptibility in Korean chil-
dren infected with H. pylori will be necessary.
Clarithromycin and metronidazole are important key anti-
biotics in the treatment of H. pylori infection especially in
children, so increasing resistance to both antibiotics has be-
come a major problem in eradication, including in children
(6-8, 14, 15). In Korean children, the resistance rate of H. pylori
to clarithromycin was 19% in 2000 (16) and that in our un-
published personal data in 2005 was 33% (unpublished per-
sonal data in 9 children). These results suggest that the rate
of clarithromycin is increasing in Korean children. Those in
Korean adult also showed increasing rate of resistance from
7.1% in 1999 to 13.8% in 2003 (17). For example, of chil-
dren infected with H. pylori, the rate of resistance to clarithro-
mycin has been reported to range from 12.4% to 23.5% in
Europe, from 10.6% to 25% in North America, and from
5.4% to 17% in East Asia (8).
The essential risk factor for clarithromycin resistance is pre-
vious consumption of macrolides (18-20). Macrolides, which
include clarithromycin, azithromycin, and erythromycin, have
been used in Korea since the early 1990s to treat children with
respiratory tract infections, enterocolitis, otitis media, and
chronic sinusitis. During macrolides treatment, H. pylori col-
onizing the stomach of a child may become resistant to clar-
ithromycin, leading to high rates of primary clarithromycin
resistance (21).
Metronidazole has been used as a primary antimicrobial
agent to treat H. pylori infection because it is actively secret-
ed in the saliva and gastric juice, becoming highly concen-
trated in the stomach. In Europe and the U.S.A., the preva-
lence of H. pylori resistance to metronidazole has been found
to vary from 20% to 40% (22-24), and its prevalence is much
higher in developing countries (50-80%) (25). In contrast,
H. pylori resistance to metronidazole is quite low in Japan
(9-12%) (26). In Korean adult, H. pylori resistance to metron-
idazole has increased from 52.9% in 1987 to 66.2% in 2003
(17). In Korean children in our unpublished personal data in
2005 was 44% (unpublished personal data in 9 children).
Recently, doubly resistant strains have been reported world-
wide, but their prevalence is still low in Europe (0.8-9.1%)
and Asia (2-3%) (27, 28). In our study, 6 children failed treat-
ment with both the OAC and BAM regimens, suggesting
that they may harbor multi-drug resistant strains of H. pylori
and in our unpublished data 33% children showed resistance
to both clarithromycin and metronidazole.
We changed OAC as first-line treatment since 2001, be-
cause NASPGHN (North American Society for Pediatric
Gastroenterology, Hepatology and Nutrition) (5) recommend-
ed bismuth compound as second-line treatment because of
the availability and clinician’s reluctance to use bismuth com-
pound, however BAM regimen showed superior eradication
rate to OAC regimen. 
In some studies, poor compliance has been a major risk
factor for failure to eradicate H. pylori infection (29). In our
study, the compliance was not investigated, so we could not
estimate the compliance issue.
Our study had several limitations. Firstly, we could not
evaluate compliance and eradication rate to intention to treat
and per protocol since it was not a randomized controlled
study, although we found no demographic differences between
children treated with the two triple regimens. Secondly we
do not have antibiotic susceptibility testing data, which might
have given more detailed information.
In conclusion, we have compared the efficacy of a metron-
idazole-based regimen and a clarithromycin-based regimen
in a large population of children infected with H. pylori. Our
study showed that the triple therapy with BAM was more
effective for the first-line eradication of H. pylori infection in
Korean children, but has no statistical difference with OAC
regimen.
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